Cellectar Poised for Breakout with Key EMA Filing
AI Prediction of Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, with its proprietary Phospholipid Drug Conjugate™ (PDC) platform, is poised for significant clinical advancements in cancer treatment, focusing on its lead assets iopofosine I 131 and CLR 125. The upcoming EMA submission for iopofosine I 131 and the awaited early data from the CLR 125 study are key catalysts.
Cellectar Biosciences, a late-stage biopharmaceutical company, leverages its unique Phospholipid Drug Conjugate™ (PDC) platform to develop targeted therapies for cancer, with a focus on difficult-to-treat forms. Its lead asset, iopofosine I 131, is advancing towards a potential EMA submission for Waldenstrom macroglobulinemia, which could significantly impact its valuation. Concurrently, CLR 125, targeting triple-negative breast cancer (TNBC), is expected to release early clinical data, potentially validating the company's PDC platform further. These developments, coupled with a strategic focus on solid tumors, position Cellectar at a critical juncture. Success in these areas could drive substantial appreciation in CLRB's market value.
CLRB Report Information
Prediction Date2026-03-14
Close @ Prediction$3.20
Mkt Cap11m
IPO DateN/a
AI-derived Information
Recent News for CLRB
- Apr 21, 10:00 am — Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 (GlobeNewswire)
- Apr 14, 8:35 am — Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) (GlobeNewswire)
- Mar 4, 12:32 pm — Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby)
- Mar 4, 7:15 am — Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates (GlobeNewswire)
- Feb 25, 8:05 am — Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 (GlobeNewswire)
- Feb 17, 8:05 am — Cellectar Biosciences Expands Global Intellectual Property Estate (GlobeNewswire)
- Jan 9, 8:05 am — Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference (GlobeNewswire)
- Dec 16, 8:05 am — Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies (GlobeNewswire)
- Nov 13, 4:00 pm — Cellectar Biosciences Inc (CLRB) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
- Nov 13, 7:20 am — Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
- Nov 6, 8:05 am — Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 (GlobeNewswire)
- Oct 27, 8:30 am — Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma (GlobeNewswire)
NDAPR (News-Driven AI Prediction Revision) events for CLRB
-
Apr 21, 10:06 amRevision: MODIFIED | Price Dir: YES_UP | Thesis: ACTIVE | Reason: Earlier supportive data catalyst added before EMA filingWindow: 2026-05-29 to 2026-12-31Target: 7.00 | Prob: 68%Catalyst: ASCO WaM subset data presentation and EMA submission for iopofosine I 131Rationale: Catalyst progress. ASCO poster acceptance adds a nearer efficacy-focused sentiment catalyst before the still-pending Q3 2026 EMA submission, modestly improving odds.
-
Apr 14, 8:47 amRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason: Catalyst progressRationale: Enrollment in CLR 125 trial marks progress, aligning with ongoing catalyst expectations.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest